Category: Iran

How much proof do you want? Hundreds of studies conclude – treat Covid-19 early with hydroxychloroquine!

HCQ is effective for COVID-19. The probability that an ineffective treatment generated results as positive as the 235 studies to date is estimated to be 1 in 6 quadrillion (p = 0.00000000000000018).
Early treatment is most successful, with 100% of 29 studies reporting a positive effect (13 statistically significant in isolation) and an estimated reduction of 65% in the effect measured (death, hospitalization, etc.) using a random effects meta-analysis, RR 0.35 [0.25-0.50].
92% of Randomized Controlled Trials (RCTs) for early, PrEP, or PEP treatment report positive effects, the probability of this happening for an ineffective treatment is 0.0017.

Read More »

Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting

Our investigation of a large national cohort appears to support early administration (within the first 3 to 7 days of COVID-19 diagnosis) of HCQ in mild COVID-19 disease in an outpatient setting for reducing hospitalizations and deaths without any serious adverse HCQ-related effects.
If this finding is confirmed in future clinical trials, HCQ as a cheap and available drug may still play a role in a specific population with respect to reducing COVID-19 burden, particularly in resource-poor countries.

Read More »

Iran: Covid-19 Study, a comprehensive investigation from exposure to treatment outcomes – HCQ a treatment option

Source: medRxiv  View ORCID Profile Mohammad Ali Ashraf,  Nasim Shokouhi,  Elham Shirali, Fateme Davari-tanha, Omeed Memar,   View ORCID Profile Alireza Kamalipour,  Ayein Azarnoush,  Avin Mabadi,  Adele Ossareh,  Milad Sanginabadi,  Talat Mokhtari Azad,  Leila Aghaghazvini,  Sara Ghaderkhani,  Tahereh Poordast,  Alieh Pourdast,  Pershang  Nazemi

Read More »